Compare Stocks: GILD, DOW, and ETD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DOW DOW	$30.50 +0.6%	$29.92	$20.65 ▼ $42.74	$22.04B	0.44	8.43 million shs	5.96 million shs
ETD Ethan Allen Interiors	$23.45 +0.2%	$22.73	$18.28 ▼ $30.80	$597.22M	1.02	542,632 shs	723,851 shs
GILD Gilead Sciences	$145.68 -2.1%	$134.25	$108.46 ▼ $157.29	$180.64B	0.32	6.47 million shs	3.95 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DOW DOW	+0.57%	-5.60%	+0.01%	-9.72%	+23.22%
ETD Ethan Allen Interiors	+0.21%	+0.09%	-0.76%	+13.54%	-21.78%
GILD Gilead Sciences	-2.14%	-0.30%	+9.76%	+8.37%	+27.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DOW DOW	$30.50 +0.6%	$29.92	$20.65 ▼ $42.74	$22.04B	0.44	8.43 million shs	5.96 million shs
ETD Ethan Allen Interiors	$23.45 +0.2%	$22.73	$18.28 ▼ $30.80	$597.22M	1.02	542,632 shs	723,851 shs
GILD Gilead Sciences	$145.68 -2.1%	$134.25	$108.46 ▼ $157.29	$180.64B	0.32	6.47 million shs	3.95 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DOW DOW	+0.57%	-5.60%	+0.01%	-9.72%	+23.22%
ETD Ethan Allen Interiors	+0.21%	+0.09%	-0.76%	+13.54%	-21.78%
GILD Gilead Sciences	-2.14%	-0.30%	+9.76%	+8.37%	+27.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DOW DOW	2.43	Hold	$35.56	16.58% Upside
ETD Ethan Allen Interiors	1.33	Sell	$22.00	-6.18% Downside
GILD Gilead Sciences	2.83	Moderate Buy	$158.04	8.48% Upside

Current Analyst Ratings Breakdown

Latest GILD, DOW, and ETD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	GILD Gilead Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C-)
8/7/2026	DOW DOW	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/5/2026	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$120.00 ➝ $123.00
8/5/2026	GILD Gilead Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$155.00
8/5/2026	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$170.00
7/31/2026	ETD Ethan Allen Interiors	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
7/30/2026	ETD Ethan Allen Interiors	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/30/2026	ETD Ethan Allen Interiors	Telsey Advisory Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Perform	$24.00 ➝ $22.00
7/29/2026	GILD Gilead Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/29/2026	GILD Gilead Sciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$155.00 ➝ $145.00
7/27/2026	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$166.00 ➝ $165.00

(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DOW DOW	$39.97B	0.55	$3.03 per share	10.06	$24.04 per share	1.27
ETD Ethan Allen Interiors	$579.49M	1.03	$2.66 per share	8.80	$18.53 per share	1.27
GILD Gilead Sciences	$29.44B	6.14	$10.47 per share	13.91	$9.47 per share	15.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DOW DOW	-$2.62B	-$1.82	N/A	17.63	0.38	-3.13%	3.26%	0.96%	10/22/2026 (Estimated)
ETD Ethan Allen Interiors	$39.88M	$1.56	15.03	N/A	N/A	6.88%	7.88%	5.17%	10/28/2026 (Estimated)
GILD Gilead Sciences	$8.51B	-$2.67	N/A	14.79	N/A	-10.64%	-2.11%	-0.75%	10/29/2026 (Estimated)

Latest GILD, DOW, and ETD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/3/2026	Q2 2026	GILD Gilead Sciences	-$7.25	-$6.75	+$0.50	-$8.45	$7.40 billion	$7.80 billion
7/29/2026	Q4 2026	ETD Ethan Allen Interiors	$0.3350	$0.36	+$0.0250	$0.46	$148.70 million	$146.75 million
7/23/2026	Q2 2026	DOW DOW	$1.25	$1.44	+$0.19	$0.99	$12.03 billion	$12.09 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DOW DOW	$1.40	4.59%	-5.59%	N/A	N/A
ETD Ethan Allen Interiors	$1.56	6.65%	+1.14%	100.00%	1 Years
GILD Gilead Sciences	$3.28	2.25%	+3.04%	N/A	10 Years

Latest GILD, DOW, and ETD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	GILD Gilead Sciences	quarterly	$0.82	2.43%	9/15/2026	9/15/2026	9/29/2026
8/19/2026	ETD Ethan Allen Interiors	special	$3.00		9/3/2026	9/3/2026	9/17/2026
8/12/2026	DOW DOW	quarterly	$0.35	4.58%	8/31/2026	8/31/2026	9/11/2026
7/28/2026	ETD Ethan Allen Interiors	special	$0.25		8/12/2026	8/12/2026	8/26/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DOW DOW	0.99	1.75	1.14
ETD Ethan Allen Interiors	N/A	2.06	1.06
GILD Gilead Sciences	2.03	1.27	1.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DOW DOW	64.00%
ETD Ethan Allen Interiors	83.80%
GILD Gilead Sciences	83.67%

Insider Ownership

Company	Insider Ownership
DOW DOW	0.50%
ETD Ethan Allen Interiors	9.92%
GILD Gilead Sciences	0.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DOW DOW	34,600	722.34 million	718.73 million	Optionable
ETD Ethan Allen Interiors	3,211	25.45 million	22.92 million	Optionable
GILD Gilead Sciences	17,000	1.24 billion	1.24 billion	Optionable

GILD, DOW, and ETD Headlines

Recent News About These Companies

Wellington Management Group LLP Sells 838,308 Shares of Gilead Sciences, Inc. $GILD

August 29 at 7:13 AM | marketbeat.com

Royal London Asset Management Ltd. Lowers Position in Gilead Sciences, Inc. $GILD

August 29 at 7:06 AM | marketbeat.com

Nissay Asset Management Corp Japan Boosts Position in Gilead Sciences, Inc. $GILD

August 29 at 6:49 AM | marketbeat.com

Rakuten Investment Management Inc. Raises Stock Holdings in Gilead Sciences, Inc. $GILD

August 29 at 6:17 AM | marketbeat.com

Braun Stacey Associates Inc. Takes Position in Gilead Sciences, Inc. $GILD

August 29 at 4:58 AM | marketbeat.com

Archer Investment Corp Takes Position in Gilead Sciences, Inc. $GILD

August 29 at 3:56 AM | marketbeat.com

BNP Paribas Purchases 20,329 Shares of Gilead Sciences, Inc. $GILD

August 29 at 3:40 AM | marketbeat.com

Beacon Pointe Advisors LLC Reduces Holdings in Gilead Sciences, Inc. $GILD

August 29 at 3:29 AM | marketbeat.com

Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo

August 28 at 1:31 PM | tipranks.com

Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection

August 28 at 11:46 AM | zacks.com

Gilead’s Bixlenvo gains US approval

August 28 at 9:34 AM | thepharmaletter.comT

4 stocks to watch on Friday: MRNA, GILD, JBLU, and LLY

August 28 at 9:34 AM | seekingalpha.com

Gilead once-daily HIV pill approved in U.S.

August 28 at 9:34 AM | seekingalpha.com

Gilead Sciences (NASDAQ:GILD) Director Anthony Welters Sells 18,000 Shares

August 28 at 6:36 AM | insidertrades.com

Glenview Trust Co Makes New $26.78 Million Investment in Gilead Sciences, Inc. $GILD

August 28 at 6:32 AM | marketbeat.com

United Capital Financial Advisors LLC Trims Stake in Gilead Sciences, Inc. $GILD

August 28 at 6:25 AM | marketbeat.com

Public Employees Retirement System of Ohio Trims Stock Holdings in Gilead Sciences, Inc. $GILD

August 28 at 6:00 AM | marketbeat.com

Empowered Funds LLC Acquires 30,382 Shares of Gilead Sciences, Inc. $GILD

August 28 at 4:39 AM | marketbeat.com

Dearborn Partners LLC Makes New $9.74 Million Investment in Gilead Sciences, Inc. $GILD

August 28 at 4:32 AM | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $5.87 Million in Gilead Sciences, Inc. $GILD

August 28 at 3:51 AM | marketbeat.com

Bamco Inc. NY Sells 12,000 Shares of Gilead Sciences, Inc. $GILD

August 28 at 3:27 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GILD, DOW, and ETD Company Descriptions

DOW NYSE:DOW

$30.50 +0.17 (+0.56%)

As of 08/28/2026 03:58 PM Eastern

Dow, Inc. is a materials science company, which engages in the development of innovative solutions. It operates through the following segments: Packaging and Specialty Plastics, Industrial Intermediates and Infrastructure, and Performance Materials and Coatings. The Packaging and Specialty Plastics segment consists of hydrocarbons and energy and packaging and specialty plastics. The Industrial Intermediates and Infrastructure segment covers the industrial solutions and polyurethanes and construction chemicals. The Performance Materials and Coatings segment includes coatings and performance monomers and consumer solutions. The company was founded in 1897 and is headquartered in Midland, MI.

Ethan Allen Interiors NYSE:ETD

$23.45 +0.04 (+0.17%)

As of 08/28/2026 03:58 PM Eastern

Ethan Allen Interiors Inc. operates as an interior design company, and manufacturer and retailer of home furnishings in the United States, Mexico, Honduras, and Canada. The company operates in two segments, Wholesale and Retail. Its products include case goods items, such as beds, dressers, armoires, tables, chairs, buffets, entertainment units, home office furniture, and wooden accents; upholstery comprising fabric-covered items, such as sleepers, recliners and other motion furniture, chairs, ottomans, custom pillows, sofas, loveseats, cut fabrics, and leather; and home accent items consisting of window treatments and drapery hardware, wall decors, florals, lighting, clocks, mattresses, bedspreads, throws, pillows, decorative accents, area rugs, wall coverings, and home and garden furnishings. The company markets and sells its products under the Ethan Allen brand through home furnishing retail networks and independent retailers, as well as through ethanallen.com website. It operates a network of design centers. Ethan Allen Interiors Inc. was founded in 1932 and is headquartered in Danbury, Connecticut.

Gilead Sciences NASDAQ:GILD

$145.68 -3.18 (-2.14%)

As of 08/28/2026 04:00 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GILD, DOW, and ETD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GILD, DOW, and ETD Earnings

Compare Dividends

Latest GILD, DOW, and ETD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GILD, DOW, and ETD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GILD, DOW, and ETD Company Descriptions

DOW NYSE:DOW

Ethan Allen Interiors NYSE:ETD

Gilead Sciences NASDAQ:GILD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GILD, DOW, and ETD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GILD, DOW, and ETD Earnings

Compare Dividends

Latest GILD, DOW, and ETD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GILD, DOW, and ETD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GILD, DOW, and ETD Company Descriptions

DOW NYSE:DOW

Ethan Allen Interiors NYSE:ETD

Gilead Sciences NASDAQ:GILD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools